MaaT Pharma Announces Positive Interim Engraftment Data for Oral Formulation MaaT033 Allowing Early Termination of Phase 1b CIMON Study
Retrieved on:
Monday, January 24, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Biomarker, Euronext Paris, Survival, Forward-looking statement, Patient, Human, Degenerative disease, Safety, Incidence, MET, CIMON, OTU, Operational taxonomic unit, Maat, CEO, Data monitoring committee, Acute myeloid leukemia, Bacteria, Graft-versus-host disease, Enema, Company, 16S, CGMP, MD, Capsule, Cancer, Pharmaceutical industry, Dietary supplement, Antibiotics, MaaT033, MaaT Pharma, MAAT033, MAAT PHARMA
Complete results from the Phase 1b CIMON trial are expected in the first half of 2022.
Key Points:
- Complete results from the Phase 1b CIMON trial are expected in the first half of 2022.
- These interim results are an important milestone for MaaT Pharma as MaaT033 is our second drug candidate and our first oral formulation, to demonstrate proof of engraftment in humans, said Herv Affagard, CEO and co-founder of MaaT Pharma.
- MaaT033 is intended to improve survival outcomes in hemato-oncology patients receiving allo-HSCT by protecting and restoring their gut microbiome.
- We look forward to further exploring the data from CIMON and preparing for a Phase 2/3 trial start.